JP2015517459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517459A5 JP2015517459A5 JP2015509461A JP2015509461A JP2015517459A5 JP 2015517459 A5 JP2015517459 A5 JP 2015517459A5 JP 2015509461 A JP2015509461 A JP 2015509461A JP 2015509461 A JP2015509461 A JP 2015509461A JP 2015517459 A5 JP2015517459 A5 JP 2015517459A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- aib
- pro
- glu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 18
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- -1 15- carboxy - pentadecanoyl Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642439P | 2012-05-03 | 2012-05-03 | |
| US61/642,439 | 2012-05-03 | ||
| US201361765561P | 2013-02-15 | 2013-02-15 | |
| US61/765,561 | 2013-02-15 | ||
| PCT/EP2013/059319 WO2013164483A1 (en) | 2012-05-03 | 2013-05-03 | Gip-glp-1 dual agonist compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517459A JP2015517459A (ja) | 2015-06-22 |
| JP2015517459A5 true JP2015517459A5 (OSRAM) | 2016-06-23 |
| JP6228187B2 JP6228187B2 (ja) | 2017-11-08 |
Family
ID=48325702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509461A Active JP6228187B2 (ja) | 2012-05-03 | 2013-05-03 | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10100097B2 (OSRAM) |
| EP (1) | EP2844669B1 (OSRAM) |
| JP (1) | JP6228187B2 (OSRAM) |
| KR (1) | KR102184241B1 (OSRAM) |
| CN (1) | CN104470948B (OSRAM) |
| AR (1) | AR090937A1 (OSRAM) |
| AU (1) | AU2013255751B2 (OSRAM) |
| BR (1) | BR112014027348B1 (OSRAM) |
| CA (1) | CA2872314C (OSRAM) |
| EA (1) | EA028665B1 (OSRAM) |
| HK (1) | HK1208232A1 (OSRAM) |
| IL (1) | IL235463A0 (OSRAM) |
| IN (1) | IN2014MN02304A (OSRAM) |
| MX (1) | MX356641B (OSRAM) |
| NZ (1) | NZ702333A (OSRAM) |
| PH (1) | PH12014502452A1 (OSRAM) |
| SG (1) | SG11201407137PA (OSRAM) |
| TR (1) | TR201815338T4 (OSRAM) |
| TW (1) | TWI689515B (OSRAM) |
| WO (1) | WO2013164483A1 (OSRAM) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| IN2014MN02304A (OSRAM) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20150344540A1 (en) * | 2012-12-19 | 2015-12-03 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| WO2014192284A1 (en) | 2013-05-28 | 2014-12-04 | Takeda Pharmaceutical Company Limited | Peptide compound |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| RS57632B1 (sr) | 2013-10-17 | 2018-11-30 | Zealand Pharma As | Acilovani analozi glukagona |
| CN105849122B (zh) * | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
| JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物 |
| CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| TWI705973B (zh) * | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| WO2017060500A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US10577905B2 (en) | 2018-02-12 | 2020-03-03 | Eagle Technology, Llc | Hydrocarbon resource recovery system and RF antenna assembly with latching inner conductor and related methods |
| WO2019193204A1 (en) | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| AU2019263674B2 (en) * | 2018-05-04 | 2023-03-02 | Novo Nordisk A/S | GIP derivatives and uses thereof |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| TW202523681A (zh) | 2018-07-23 | 2025-06-16 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
| UA128697C2 (uk) | 2018-07-23 | 2024-10-02 | Елі Ліллі Енд Компані | Способи застосування коагоніста gip/glp-1 для терапії |
| CN112469431A (zh) | 2018-07-23 | 2021-03-09 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| JP2022503793A (ja) * | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| US20220127323A1 (en) * | 2019-01-07 | 2022-04-28 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic uses thereof |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| EP4017866A1 (en) | 2019-08-19 | 2022-06-29 | Eli Lilly and Company | Methods of making incretin analogs |
| WO2021066600A1 (ko) | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| PH12022551101A1 (en) | 2019-11-11 | 2023-11-13 | Boehringer Ingelheim Int | Npy2 receptor agonists |
| WO2021093883A1 (zh) * | 2019-11-15 | 2021-05-20 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
| WO2021143810A1 (zh) * | 2020-01-17 | 2021-07-22 | 珠海联邦制药股份有限公司 | 多肽化合物及其应用 |
| KR20220131292A (ko) | 2020-01-23 | 2022-09-27 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공동-효능제 화합물 |
| AU2021241257A1 (en) * | 2020-03-25 | 2022-10-13 | Takeda Pharmaceutical Company Limited | QD dosing of GIP receptor agonist peptide compounds and uses thereof |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| CA3184723A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Glp-1 and gip receptor co-agonists |
| BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
| WO2022049310A1 (en) | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| MX2023002906A (es) | 2020-10-17 | 2023-04-05 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip. |
| US20240067702A1 (en) * | 2020-12-02 | 2024-02-29 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Lactam-modified polypeptide compounds |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| WO2022133797A1 (zh) * | 2020-12-23 | 2022-06-30 | 浙江道尔生物科技有限公司 | 一种长效胰高血糖素衍生物 |
| IL304214B2 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | Compositions and methods for treating metabolic and liver disorders |
| EP4333814A1 (en) | 2021-05-07 | 2024-03-13 | Eli Lilly and Company | Erodible tablet |
| CN117015551B (zh) * | 2021-05-28 | 2024-05-28 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
| CA3222051A1 (en) * | 2021-06-01 | 2022-12-08 | Nanjing Zhihe Medicine Technology Co., Ltd. | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
| EP4410827A1 (en) * | 2021-09-02 | 2024-08-07 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116947978A (zh) * | 2022-04-19 | 2023-10-27 | 北京惠之衡生物科技有限公司 | 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂 |
| JP2025523681A (ja) | 2022-07-13 | 2025-07-23 | 杭州中美華東製薬有限公司 | Ｇｌｐ－１／ｇｉｐ二重アゴニスト、その調製方法および使用 |
| CA3261877A1 (en) * | 2022-07-15 | 2024-01-18 | Pep2Tango Therapeutics Inc. | COMPOSITIONS COMPRISING MULTI-AGONIST PEPTIDES, MANUFACTURING PROCESSES AND METHODS OF USE |
| KR20250037781A (ko) * | 2022-07-20 | 2025-03-18 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애 치료를 위한 약학 제제 및 방법 |
| KR20250057847A (ko) | 2022-08-29 | 2025-04-29 | 일라이 릴리 앤드 캄파니 | 경구 전달용 조성물 |
| JP2025531200A (ja) | 2022-09-15 | 2025-09-19 | イーライ リリー アンド カンパニー | Ｇｉｐ及びｇｌｐ－１二重アゴニスト化合物 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| CR20250313A (es) | 2023-01-31 | 2025-08-26 | Lilly Co Eli | Agonistas del trirreceptor gip/glp1/gcg y usos de estos |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
| WO2024242410A1 (ko) | 2023-05-19 | 2024-11-28 | 주식회사 아울바이오 | 티르제파타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물 |
| WO2024252366A1 (en) | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| WO2025003471A1 (en) | 2023-06-30 | 2025-01-02 | Zealand Pharma A/S | Combination therapy |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| DK0929567T3 (da) | 1996-09-09 | 2005-06-27 | Zealand Pharma As | Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese |
| AU724326B2 (en) | 1996-09-09 | 2000-09-14 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| EP1066314B1 (en) | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE69922043T2 (de) | 1998-12-07 | 2005-11-24 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Glp-1 analoge |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CN1344248A (zh) | 1999-03-17 | 2002-04-10 | 诺沃挪第克公司 | 肽的酰化方法和新酰化剂 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| AU2004234345A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| ES2735533T3 (es) | 2004-11-12 | 2019-12-19 | Novo Nordisk As | Formulaciones estables de GLP-1 |
| CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP1883419A4 (en) * | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| PL1891105T3 (pl) | 2005-06-13 | 2012-09-28 | Imperial Innovations Ltd | Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| CN101432025B (zh) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
| ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| US20090318353A1 (en) * | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| KR101656107B1 (ko) | 2007-11-20 | 2016-09-08 | 암브룩스, 인코포레이티드 | 변형된 인슐린 폴리펩티드 및 이의 용도 |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| KR20110021758A (ko) | 2008-04-22 | 2011-03-04 | 케이스 웨스턴 리저브 유니버시티 | 이형체-특이적 인슐린 유사체 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| EP2307037A4 (en) | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| CA2728284C (en) | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| MY158627A (en) | 2008-07-31 | 2016-10-31 | Univ Case Western Reserve | Halogen-stabilized insulin |
| KR20110043686A (ko) | 2008-08-07 | 2011-04-27 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 |
| CN106317164A (zh) | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| PL2370461T3 (pl) | 2008-12-15 | 2014-03-31 | Zealand Pharma As | Analogi glukagonu |
| PL2370462T3 (pl) | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| MX2011006313A (es) | 2008-12-15 | 2011-09-27 | Zealand Pharma As | Analogos de glucagon. |
| US8642540B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| WO2010107487A2 (en) | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| HUE027229T2 (en) | 2009-12-16 | 2016-08-29 | Novo Nordisk As | Double acylated glp-1 derivatives |
| NZ601167A (en) | 2010-01-20 | 2014-12-24 | Zealand Pharma As | Treatment of cardiac conditions |
| CN102834108A (zh) | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| CN102933598A (zh) | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| BR112012027545B1 (pt) | 2010-04-27 | 2020-09-24 | Betta Pharmaceuticals Co., Ltd. | Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| ES2683372T3 (es) | 2010-11-09 | 2018-09-26 | Novo Nordisk A/S | Derivados de GLP-1 acilados con un conector nuevo |
| AR085086A1 (es) | 2011-01-20 | 2013-09-11 | Zealand Pharma As | Uso de analogos de glucagon acilados |
| EP2691108A1 (en) | 2011-03-28 | 2014-02-05 | Novo Nordisk A/S | Novel glucagon analogues |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
| CN104093735B (zh) | 2011-09-23 | 2018-07-06 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| EA201490982A1 (ru) | 2011-12-23 | 2015-01-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| IN2014MN02304A (OSRAM) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| RS57632B1 (sr) | 2013-10-17 | 2018-11-30 | Zealand Pharma As | Acilovani analozi glukagona |
| CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
| MX2016010599A (es) | 2014-02-18 | 2016-11-18 | Novo Nordisk As | Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
-
2013
- 2013-05-03 IN IN2304MUN2014 patent/IN2014MN02304A/en unknown
- 2013-05-03 TW TW102115949A patent/TWI689515B/zh active
- 2013-05-03 AR ARP130101524A patent/AR090937A1/es unknown
- 2013-05-03 KR KR1020147033952A patent/KR102184241B1/ko active Active
- 2013-05-03 SG SG11201407137PA patent/SG11201407137PA/en unknown
- 2013-05-03 AU AU2013255751A patent/AU2013255751B2/en active Active
- 2013-05-03 CA CA2872314A patent/CA2872314C/en active Active
- 2013-05-03 TR TR2018/15338T patent/TR201815338T4/tr unknown
- 2013-05-03 EP EP13720931.8A patent/EP2844669B1/en active Active
- 2013-05-03 CN CN201380032714.4A patent/CN104470948B/zh active Active
- 2013-05-03 JP JP2015509461A patent/JP6228187B2/ja active Active
- 2013-05-03 US US14/398,260 patent/US10100097B2/en active Active
- 2013-05-03 MX MX2014013318A patent/MX356641B/es active IP Right Grant
- 2013-05-03 BR BR112014027348-0A patent/BR112014027348B1/pt active IP Right Grant
- 2013-05-03 WO PCT/EP2013/059319 patent/WO2013164483A1/en not_active Ceased
- 2013-05-03 EA EA201491918A patent/EA028665B1/ru not_active IP Right Cessation
- 2013-05-03 HK HK15108788.2A patent/HK1208232A1/xx unknown
- 2013-05-03 NZ NZ702333A patent/NZ702333A/en unknown
-
2014
- 2014-11-02 IL IL235463A patent/IL235463A0/en unknown
- 2014-11-03 PH PH12014502452A patent/PH12014502452A1/en unknown
-
2018
- 2018-09-05 US US16/121,745 patent/US20190135886A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517459A5 (OSRAM) | ||
| JP2020045362A5 (OSRAM) | ||
| JP2013517307A5 (OSRAM) | ||
| JP2023126965A5 (OSRAM) | ||
| TWI689515B (zh) | Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法 | |
| JP2021138740A5 (OSRAM) | ||
| JP2020040979A (ja) | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 | |
| HRP20171499T1 (hr) | Protutijela za humani gdf8 | |
| JP2015524419A5 (OSRAM) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009043466A3 (en) | Therapeutic use of the peptide gluten exorphin a5 | |
| JP2012520866A5 (OSRAM) | ||
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| WO2009039972A3 (en) | Use of muramyl dipeptide (mdp) as a therapeutic agent | |
| WO2009049742A3 (en) | Use of melanotrophin-potentiating factor as a therapeutic agent | |
| WO2009033768A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2013518090A5 (OSRAM) | ||
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| WO2009046832A3 (en) | Short peptides used in medicine | |
| JP2014506579A5 (OSRAM) | ||
| JP6768646B2 (ja) | Ｐｇｉ２受容体に関連した状態の治療法 |